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The non-obese diabetic (NOD) mouse is susceptible to the development of autoimmune diabetes but also
multiple other autoimmune diseases. Over twenty susceptibility loci linked to diabetes have been
identiﬁed in NOD mice and progress has been made in the deﬁnition of candidate genes at many of these
loci (termed Idd for insulin-dependent diabetes). The susceptibility to multiple autoimmune diseases in
the NOD background is a unique opportunity to examine susceptibility genes that confer a general
propensity for autoimmunity versus susceptibility genes that control individual autoimmune diseases.
We previously showed that NOD mice deﬁcient for the costimulatory molecule B7-2 (NOD-B7-2KO mice)
were protected from diabetes but spontaneously developed an autoimmune peripheral neuropathy.
Here, we took advantage of multiple NOD mouse strains congenic for Idd loci to test the role of these Idd
loci the development of neuropathy and determine if B6 alleles at Idd loci that are protective for diabetes
will also be for neuropathy. Thus, we generated NOD-B7-2KO strains congenic at Idd loci and examined
the development of neuritis and clinical neuropathy. We found that the NOD-H-2g7 MHC region is
necessary for development of neuropathy in NOD-B7-2KO mice. In contrast, other Idd loci that signiﬁ-
cantly protect from diabetes did not affect neuropathy when considered individually. However, we found
potent genetic interactions of some Idd loci that provided almost complete protection from neuritis and
clinical neuropathy. In addition, defective immunoregulation by Tregs could supersede protection by
some, but not other, Idd loci in a tissue-speciﬁc manner in a model where neuropathy and diabetes
occurred concomitantly. Thus, our study helps identify Idd loci that control tissue-speciﬁc disease or
confer general susceptibility to autoimmunity, and brings insight to the Treg-dependence of autoimmune
processes inﬂuenced by given Idd region in the NOD background.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The non-obese diabetic (NOD) mouse strain is a prototypic
murine model of type 1 diabetes that has served as an important
tool for dissecting mechanisms involved in the breakdown of im-
mune tolerance in autoimmune diabetes [1]. In addition to diabetes,
NOD mice are prone to development of other autoimmune: þ1 415 476 0816.
tone).
versity of California, Merced,
outhwestern Medical Center,
r Ltd. Open access under CC BY-NC-Nsyndromes including: autoimmune sialadenitis [2], autoimmune
thyroiditis [3], autoimmune peripheral polyneuropathy [4], pros-
tatitis in male mice [5] and some features of non-organ-speciﬁc
autoimmune disease such as hemolytic anemia and late-onset
anti-nuclear antibodies, a systemic lupus erythematosus (SLE)-like
disease if exposed to killed mycobacterium [5e7]. Autoimmune
diseases in NOD mice share many similarities to the comparable
human diseases, including the presence of organ-speciﬁc autoan-
tibodies, autoreactive CD4þ and CD8þ T cells, and genomic synteny
of susceptibility loci. Thus, the NODmouse has been considered as a
good model for other autoimmune diseases such as Sjogren’s Syn-
drome, GuillaineBarre Syndrome and MS [4,8,9].
Autoimmune diabetes in the NOD mouse is polygenically
controlled by as many as two dozen loci (termed Idd for insulin-
dependent diabetes) distributed over 14 chromosomes [10e12].
NOD congenic strains have been developed that contain NOD
genome at all loci except for one (or a few) “introgressed” allelicD license.
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or C57BL/10 (B10) mice. These congenic models have been instru-
mental for the deﬁnition of genes and pathways that contribute to
susceptibility to autoimmune diabetes. Idd1was one of the ﬁrst loci
to be identiﬁed in the NOD mouse and spans the major histocom-
patibility complex (MHC) region of the NOD mouse [13e17]. NOD
mice harbor a unique MHC haplotype, termed H-2g7, which is
necessary for the development of diabetes and represents the
highest genetic contributor to disease susceptibility [18]. The exact
gene or regulatory elements that are responsible for the effects of
other Idd loci on disease still await identiﬁcation but candidate genes
have been identiﬁed for several Idd loci that are strong contributors
to diabetes [10,11]. Besides the MHC, Idd3 on chromosome 3
disproportionately contributes to the development of disease. NOD
mice congenic for the Idd3 locus have a strongly reduced incidence of
diabetes and candidate genes include IL-2 and IL-21 [19e24]. Other
individual Idd loci alter the development of diabetes to various de-
grees but interactions of protective alleles can confer stronger pro-
tection against diabetes in NOD mice. For example, introgressed B6
alleles for Idd5 or Idd10/Idd18 are almost fully protective for insulitis
and diabetes when combined with the B6 Idd3 region but they have
more modest effects in isolation [23,25e28].
We previously showed that NOD mice deﬁcient for the cos-
timulatory molecule B7-2 (NOD-B7-2KO mice) were protected
from autoimmune diabetes and sialadenitis but spontaneously
developed autoimmune peripheral polyneuropathy [4]. NOD-B7-
2KO mice exhibit limb paralysis associated with severe demye-
lination in the peripheral nerves beginning at 20e25 wk of age,
and the disease affected 80e100% of NOD-B7-2KO females and
30e40% males by 30e35 wk of age [4]. Peripheral neuropathy in
NOD-B7-2KO mice is dependent on interferon-gamma (IFN-g)-
producing CD4þ T cells that include autoreactive CD4þ T cells
speciﬁc for peripheral nerve antigens such as myelin protein zero
(P0) [4,29,30]. Autoimmune peripheral polyneuropathy has
also been described in NOD mice after disruption of various
pathways involved in immune tolerance such as IL-2, PD-1 or
the autoimmune regulator (Aire) and appears to have compara-
ble immunopathogenic properties as the NOD-B7-2KO disease
[31e33]. In particular, NOD mice partially deﬁcient in Aire
function develop peripheral neuropathy that is mediated by
CD4þ T cells targeting myelin P0 and IFN-g is required for dis-
ease to develop [33e35], similar to what has been observed in
NOD-B7-2KO mice [4,29,30]. In contrast, peripheral poly-
neuropathy does not occur in mice deﬁcient for B7-2, Aire or
PD-1 on B6 or mixed B6-129 backgrounds. This suggested that
development of autoimmune peripheral neuropathy on the NOD
background may be related to its genetic propensity to autoim-
munity. Additionally, T cell responses and autoAbs directed at
Schwann cells surrounding the pancreatic islets of Langerhans
have been detected in NOD mice, and it was suggested that the
insulitis that precedes overt clinical diabetes may be, in part,
directed against this peri-islet Schwann cell network. NOD mice
have also been shown to be susceptible to autoimmunity tar-
geting the central nervous system and can develop experimental
autoimmune encephalomyelitis (EAE) [9,36]. Taken together,
these data raised the possibility that common genes and path-
ways may be implicated in autoimmune pathologies targeting
the pancreatic islets and the nervous system in the NOD mouse.
In this study, we examined this question by focusing on loci
previously shown to confer susceptibility to autoimmune dia-
betes in NOD mice by crossing NOD-B7-2KO to selected NOD
congenic strains in order to compare the genetic control of
autoimmune diabetes versus neuropathy. The studies showed
that there is only a partial overlap in the genetic control of
diabetes versus neuropathy in the NOD background.2. Materials and methods
2.1. Mice
NOD-B7-2KO mice have been described previously [4]. NOD mice
congenic for Idd1 (H-2h4 andH-2b), Idd3, Idd5, Idd9, and Idd10/18were
obtained from Taconic. NODmice congenic for Idd4 [37] were gener-
ously provided by Qing-ShengMi (Henry Ford Immunology Program,
Detroit, MI). NOD-B7-2KO mice were crossed to individual NOD-Idd
congenic mice and F1 mice (heterozygous for B7-2 and Idd alleles)
were intercrossed to generate NOD-B7-2KO-Idd congenic mice. The
genotype for B7-2was determined by PCRof tail DNAas described [4].
The genotype for Idd1 was determined by ﬂow cytometry of PBMCs
isolated from the tail vein using mAbs against H-2Kd and I-Ag7 (NOD
allele), H-2Kk (H-2h4 allele) and H-2Kb (H-2b allele). The genotype for
other Idd loci was determined by PCR using primer pairs speciﬁc for
DNA segments including Idd3 (ATGAGTTGGGAAGCTTGTGC and
GTAAAGGCCAAGGGAAAAGG for marker D3nds36), Idd4 (TAA-
GAACCTTCTGTAGTTATT and ACCTTAGTTAGAGTTGGTCTC for marker
D11Nds1; TTTCATGACCCCTAATTTCCC and GTGGGTGTGCCTGTCAATC
for marker D11Mit39), Idd5 (TCTAGGTTCCTGGGATAGAATCC and
ATAGAAGCAGACCCAGAAGCC for marker D1Mit74; TATTGTTTATG-
GAAATTGGACCC and CATCTCTGAAGGAAAAAGTGCA for marker
D1Mit132), Idd9 (TGGTCATGTGTGTCCATGC and ACTTCATGTAGC-
CAGGTGGG for D4Mit233; GACAAACCACATGTAATGTGTGG and
CTGCCTGCAGGCTGTATGTA for marker D4Mit180), and Idd10/18
(TAGACCAATCTTGGGAGTGTCC and GGAAAAGCATAAGAAACAACCG
for marker D3Mit12; ATCTGAGCAATCCAGAGTTAGTCA and GCAACCT
CTGCATGCATG for marker D3Mit300). Indicated mice were treated
with 50 mg anti-B7-1mAbs every other day for 14 days between 2 and
4 weeks of age. Neuropathy and diabetes were assessed weekly as
previously described [4,29]. Only female mice were used except
where indicated. All mice were housed in a speciﬁc pathogen-free
facility at The University of California at San Francisco. All animal ex-
periments were approved by the Institutional Animal Care and Use
Committee of the University of California, San Francisco.
2.2. Histology
For histological analysis, tissues were ﬁxed in formalin and
embedded in parafﬁn. Multiple 5 mm sections were stained with
hematoxylin and eosin. For scoring of sciatic nerve and thyroid
gland inﬁltration, scores of 0, 1, 2 and 3 indicate no, mild, moderate
and severe lymphocytic inﬁltration, respectively.
2.3. In vitro cytokine production
Single-cell suspensions were prepared from spleen and LN of
indicated mice. DMEM-glutamax medium (Life Technologies,
Gaithersburg, MD) supplemented with 5% heat-inactivated FCS
(Summit Biotechnology, Ft. Collins, CO), 100 U/ml penicillin, 100 U/
ml streptomycin, nonessential amino acids, 10 mM HEPES and
50 mM b-mercaptoethanol (all from Life Technologies) was used
for cell culture. For primary stimulation, spleen and LN cells
(2  105) were stimulated with anti-CD3 (0.1 or 1 mg/ml) alone or
together with anti-CD28 (1 mg/ml) mAbs. For secondary stimula-
tion, cells were stimulated with anti-CD3 (1 mg/ml) and anti-CD28
(1 mg/ml) mAbs for 7 days, with addition of 20 U/ml recombinant
human IL-2 on day 3. On day 7, cells were restimulated with anti-
CD3 with or without anti-CD28 mAbs as above. Supernatant was
harvested from triplicate cultures after one (IL-2) or two (IFN-g)
days for both primary and secondary stimulation. Levels of cyto-
kine were measured by commercial ELISA kits according
to the manufacturer’s recommendations (BD-PharMingen, San
Diego, CA).
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All statistical analyses were performed using GraphPad Prism
version 5.04. Statistical comparison of cumulative incidence curves
was performed using a Log-Rank (ManteleCox) test. Statistical
comparison of inﬁltration severity was performed using an un-
paired two-tailed ManneWhitney test. For all tests, p values < 0.05
were considered signiﬁcant.
3. Results
3.1. The NOD-H-2g7 MHC region is necessary for the development of
autoimmune peripheral neuropathy
The H-2g7 MHC region is the only locus that is required for the
development of autoimmune diabetes in NOD mice. NOD-H-2h4
congenic mice that express H-2Kk and I-Ak MHC class I and class II
alleles are completely protected from diabetes [38]. We crossed
NOD-B7-2KO mice to NOD-H-2h4 mice to generate NOD-B7-2KO-
H-2h4 mice and followed these congenic mice for the development
of neuropathy. We found that NOD-B7-2KO-H-2h4/h4 females were
completely protected from autoimmune peripheral neuropathy
(Fig. 1A) in comparison with NOD-B7-2KO-H-2g7/g7 littermates and
NOD-B7-2KO mice which all developed neuropathy by 35 weeks of
age (Fig. 1A and data not shown). Histological analysis of sciatic
nerves showed an absence of mononuclear inﬁltration in periph-
eral nerves of NOD-B7-2KO-H-2h4/h4 mice, in contrast with the
severe inﬁltration observed in NOD-B7-2KO mice (Fig. 1B). The
absence of mononuclear inﬁltrate in NOD-B7-2KO-H-2h4/h4 mice is
not the result of delayed kinetics of disease since sciatic nerves
were still free of inﬁltration in>65week-old NOD-B7-2KO-H-2h4/h420 25 30 35 40
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Fig. 1. The NOD H-2g7 MHC locus is necessary for autoimmune peripheral neuropathy
in NOD-B7-2KO mice. NOD-B7-2KO mice (H-2g7/g7) were crossed to NOD-H-2h4/h4 or
NOD-H-2b/b congenic mice to generate NOD-B7-2KO-H-2h4/h4 and NOD-B7-2KO-H-2b/b
mice. A) Congenic NOD-B7-2KO mice that were homozygous or heterozygous for H-
2g7, H-2h4 or H-2b were followed for the development of neuropathy. Cumulative
incidence of neuropathy is shown for females of indicated genotypes. Incidence curves
signiﬁcantly different from incidence in NOD-B7-2KO mice are indicated (Log-rank
(ManteleCox) test). B) H&E staining of sciatic nerves isolated from NOD-B7-2KO and
NOD-B7-2KO-H2h4/h4 mice.mice (data not shown). Surprisingly, autoimmune neuropathy
could develop in NOD-B7-2KO-H-2h4/g7 heterozygous mice, albeit
disease was signiﬁcantly delayed in NOD-B7-2KO-H-2h4/g7 mice
compared with NOD-B7-2KOg7/g7 controls (Fig. 1A). This is notably
different from autoimmune diabetes since the MHC region must be
homozygous for H-2g7 for diabetes to develop in NOD mice
[13,16,17].
To determine if this result was speciﬁc to the H-2h4 haplotype or
could be generalized to other MHC haplotypes, we crossed NOD-
B7-2KO mice to NOD-H-2b congenic mice and followed NOD-B7-
2KO-H-2b female mice for autoimmune neuropathy. In agreement
with the results obtained after introgression of H-2h4 MHC alleles,
NOD-B7-2KO mice homozygous for H-2b MHC alleles were
completely protected from peripheral neuropathy (Fig. 1A). More-
over, 100% of NOD-B7-2KO-H-2b/g7 heterozygous mice developed
neuropathy although kinetics of disease were signiﬁcantly delayed
compared to NOD-B7-2KO mice (p < 0.05). The development of
neuropathy was not signiﬁcantly different in NOD-B7-2KO-H-2b/g7
vs. NOD-B7-2KO-H-2h4/g7 mice (p ¼ 0.08). Taken together, these
data demonstrate that MHC-linked diabetogenic genes of the NOD
mouse are also required for the development of autoimmune pe-
ripheral neuropathy in NOD-B7-2KO mice. However, unlike the
development of diabetes in this setting, the NOD H-2g7 MHC locus
is dominant in the control of autoimmune neuropathy.
3.2. Individual Idd regions that contribute to susceptibility to
diabetes in NOD mice do not control the development of neuropathy
in NOD-B7-2KO mice
Wewished to determine if alleles at Idd loci other than the MHC
region that are protective for diabetes in NOD mice would also
reduce or delay the incidence of neuropathy in NOD-B7-2KO mice.
For these studies, we selected Idd loci that were previously shown
to individually afford some level of resistance to diabetes as
demonstrated by signiﬁcantly reduced and/or delayed diabetes
incidence in NOD mice congenic for these intervals. Thus, NOD-B7-
2KO mice were crossed to NOD mice congenic for Idd3, Idd4, Idd5,
Idd9 or Idd10/18 regions and resulting congenic NOD-B7-2KO fe-
males were followed for the development of neuropathy. Of note,
we used NOD congenic mice with wide intervals in Idd regions
containing several loci in order to include all susceptibility genes in
our analysis. Namely, Idd4 encompasses Idd4.1 and Idd4.2 [37], Idd5
includes Idd5.1, Idd5.2 and Idd5.3 [39,40], Idd9 encompasses Idd9.1,
Idd9.2 and Idd9.3 [41e43], and Idd10/18 includes closely linked
Idd10 and Idd18 on chromosome 3 [44,45]. Our data showed that
there was no signiﬁcant difference in the development of neurop-
athy in NOD-B7-2KO mice congenic for any of these loci as
compared to NOD-B7-2KO mice (Fig. 2). Thus, whereas alleles at
Idd3, Idd4, Idd5, Idd9, or Idd10/18 loci introgressed from diabetes-
resistant B6, B10 or NOR strains reduced the incidence of diabetes
in NOD mice, they did not confer any protection to NOD-B7-2KO
mice for development of autoimmune neuropathy.
3.3. Idd3/5 and Idd3/10/18 combinations partially protect NOD-B7-
2KO mice from neuropathy
It was previously shown in NOD mice that protective alleles at
given Idd loci could have an additive or synergistic effect when they
were concurrently introgressed in the NOD genome. In particular,
NOD mice congenic for Idd3/Idd5 or Idd3/Idd10/Idd18 were almost
completely protected from insulitis and diabetes whereas mice
congenic for Idd3, Idd5, Idd10 or Idd18 alone were not [23,25e28].
Thus, we intercrossed NOD-B7-2KOmice congenic for Idd3 to NOD-
B7-2KO mice congenic for Idd5 or Idd10/18. NOD-B7-2KO mice
congenic for Idd3 and Idd5 (NOD-B7-2KO.Idd3b6/b6.Idd5b10/b10) will
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Fig. 2. Diabetes-protective alleles at individual Idd loci do not alter the course of autoimmune peripheral neuropathy in NOD-B7-2KO mice. NOD-B7-2KO mice were crossed to NOD
mice congenic for individual Idd loci to create congenic NOD-B7-2KO strains that carry introgressed alleles from diabetes-resistant B6, B10 or NOR mice at indicated Idd loci.
Introgressed alleles at these loci were individually shown to reduce diabetes incidence by w40e100% in NOD congenic strains [10e12]. Cumulative incidence of neuropathy is
shown for NOD-B7-2KO females congenic for indicated Idd loci (triangles) and relevant cohorts of NOD-B7-2KO controls (circles).
H. Bour-Jordan et al. / Journal of Autoimmunity 45 (2013) 58e67 61hereafter be referred to as NOD-B7-2KO-Idd3/5mice, NOD-B7-2KO
mice congenic for Idd3 and Idd10/18 (NOD-B7-2KO.Idd3b6/b6.Idd10/
18b6/b6) as NOD-B7-2KO-Idd3/10/18 mice, and NOD-B7-2KO con-
trols (NOD-B7-2KO.Iddnod/nod) as NOD-B7-2KO mice. Our data
showed that B6/B10 alleles at Idd3 and Idd5 or Idd10/18 had a
synergistic protective effect on autoimmune peripheral neuropathy
since NOD-B7-2KO-Idd3/5 and NOD-B7-2KO-Idd3/10/18 females
were almost completely protected from disease (Fig. 3A). Although
the incidence of neuropathy was not statistically different between
NOD-B7-2KO-Idd3/5 and NOD-B7-2KO-Idd3/10/18 mice, histologi-
cal analyses revealed distinct levels of sciatic nerve inﬁltration in
the two congenic strains (Fig. 3B). Indeed, inﬁltration in sciatic
nerves of NOD-B7-2KO-Idd3/5 was as severe as in NOD-B7-2KO
mice whereas inﬁltration was signiﬁcantly reduced in NOD-B7-
2KO-Idd3/10/18 mice.
Since IFN-g is required for the development of neuropathy in
NOD-B7-2KO mice [29], we determined if the reduced incidence of
clinical disease despite a strong inﬁltrate in peripheral nerves of
NOD-B7-2KO-Idd3/5 mice could be due to defective IFN-g pro-
duction by T cells. Spleen and LN cells were isolated from age-
matched NOD-B7-2KO and NOD-B7-2KO-Idd3/5 mice and stimu-
lated in vitrowith anti-CD3 mAbs with or without anti-CD28 mAbs.
Production of IFN-g after primary or secondary stimulation was
measured in culture supernatants by ELISA. We could not detectany difference in IFN-g production by NOD-B7-2KO versus NOD-
B7-2KO-Idd3/5 T cells (Fig. 3C). IL-2 production was also compara-
ble in NOD-B7-2KO and NOD-B7-2KO-Idd3/5 mice (data not
shown). Similar IFN-g production by NOD-B7-2KO versus NOD-B7-
2KO-Idd3/5 T cells was observed in all conditions tested, i.e. after
primary and secondary stimulation, after stimulation with anti-
CD3 mAbs in the presence or absence of anti-CD28 mAbs, and us-
ing anti-CD3 mAbs at different concentrations (Fig. 3C and data not
shown). Thus, protection from disease in NOD-B7-2KO-Idd3/5mice
does not appear to result from a defect in IFN-g production.
3.4. Tissue- and sex-speciﬁc effects of Idd3/5 and Idd3/10/18
combinations on disease are revealed in NOD-B7-2KO mice in
conditions of defective immunoregulation
We previously showed that treatment of NOD-B7-2KO mice
with anti-B7-1 mAbs between 2 and 4 wk of age accelerated neu-
ropathy and restored diabetes, reﬂecting a breakdown in immune
regulation likely due to reduced numbers of regulatory T cells
(Tregs) [29,46]. Since anti-B7-1-treated NOD-B7-2KO mice develop
diabetes and neuropathy with similar incidence and kinetics, we
took advantage of this model to compare the inﬂuence of Idd3/5
and Idd3/10/18 loci combinations on each disease within the same
animal. As expected, 80e100% of anti-B7-1-treated NOD-B7-2KO
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Fig. 3. Differential effect of Idd3/5 and Idd3/10/18 combinations on clinical disease and
tissue inﬁltration in NOD-B7-2KO mice. NOD-B7-2KO mice congenic for Idd3 were
crossed to NOD-B7-2KO mice congenic for Idd5 or Idd10/18 to generate NOD-B7-2KO
mice congenic for both Idd3 and Idd5 (NOD-B7-2KO-Idd3/5) or Idd3 and Idd10/18
(NOD-B7-2KO-Idd3/10/18). A) Congenic females and NOD-B7-2KO control females
were followed for neuropathy as in Fig. 1. B) Sciatic nerves were isolated from age-
matched mice in indicated strains, stained with H&E and scored for inﬁltration as
indicated in Materials and methods. Statistical comparison of inﬁltration severity was
performed using the ManneWhitney test (NS: non-signiﬁcant; *: p ¼ 0.017). C) Spleen
and LN cells of NOD-B7-2KO-Idd3/5 congenic mice and NOD-B7-2KOcontrols were
stimulated with anti-CD3 þ/ anti-CD28 mAbs in primary or secondary stimulations
in vitro and IFN-g production was measured by ELISA of culture supernatants.
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10/18 (n ¼ 5), and NOD-B7-2KO (n ¼ 12) mice is shown. C) Cumulative incidence of
neuropathy and diabetes in anti-B7-1 mAbs-treated NOD-B7-2KO-Idd3/5 males and
females.
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weeks of age (Fig. 4A and B). Furthermore, whereas NOD-B7-2KO-
Idd3/5 and NOD-B7-2KO-Idd3/10/18 were protected from neurop-
athy and diabetes (Fig. 3A and data not shown), anti-B7-1 treat-
ment restored neuropathy in both congenic strains but had only a
minimal effect on diabetes (Fig. 4A and B). Indeed, 5 out of 5 anti-
B7-1-treated NOD-B7-2KO-Idd3/5 and 4 out of 5 NOD-B7-2KO-
Idd3/10/18 females became neuropathic by 30 weeks of age, but
only 2 out of 5 and 1 out of 5, respectively, developed diabetes by 30
weeks of age. Thus, Idd3/5 and Idd3/10/18 loci can differentially
inﬂuence autoimmunity in a tissue-speciﬁc manner on the NOD
background.
We previously reported that neuropathy and diabetes occurred
with similar kinetics and incidence in NOD-B7-2KO males and fe-
males treated with anti-B7-1 mAbs [29,46]. In contrast, we
observed a strong gender bias in the development of autoimmunity
in NOD-B7-2KO-Idd3/5 treated with anti-B7-1 mAbs (Fig. 4C).Whereas 5 out of 5 anti-B7-1-treated NOD-B7-2KO-Idd3/5 females
became neuropathic and 2 out of 5 developed diabetes, diabetes
and neuropathy were clinically detectable in 0 out of 5 males by 35
weeks of age. This result may reﬂect a different tropism of auto-
immunity in anti-B7-1-treated NOD-B7-2KO-Idd3/5 males vs. fe-
males. Indeed, clinical disease was associated with inﬁltration in
peripheral nerves and pancreatic islets as well as severe inﬁltration
in salivary glands in females.
3.5. Anti-B7-1 treatment differentially affects the development of
autoimmune neuropathy versus thyroiditis in NOD-B7-2KO and
NOD-B7-2KO-H-2h4 mice
In view of data in the previous section suggesting that Treg
depletion could supersede the previously established genetic con-
trol of a given disease in theNODbackground,we set out to examine
whether this would still apply in the case of theMHC locus given its
disproportionate contribution to susceptibility to autoimmunity.
Therefore, we treated NOD-B7-2KO-H-2h4congenic mice and NOD-
B7-2KO controlswith anti-B7-1mAbs between 2 and 4weeks of age
and followedmice for the development of autoimmunity. We chose
to perform these experiments in the NOD-B7-2KO-H-2h4strain
H. Bour-Jordan et al. / Journal of Autoimmunity 45 (2013) 58e67 63since, besides being protected from diabetes, NOD-H-2h4 mice
spontaneously develop autoimmune thyroiditis and represent a
model of Hashimoto’s thyroiditis in humans [47,48]. We found that
neither neuropathy nor diabetes developed by 30 weeks of age in
NOD-B7-2KO-H-2h4 mice after anti-B7-1 treatment, in contrast to
NOD-B7-2KO mice which developed both diseases with 80e100%
penetrance by 15-20 weeks of age (Fig. 5A). Moreover, histological
analyses indicated that NOD-B7-2KO-H-2h4 mice were protected
from mononuclear inﬁltration in sciatic nerves (Fig. 5B and C) and
pancreatic islets (data not shown), and this protection was unaf-
fected by treatment with anti-B7-1 mAbs (Fig. 5B and C). However,
anti-B7-1 treatment did have strong effects on autoimmunity in
NOD-B7-2KO-H-2h4mice, as revealed byH&E staining of the thyroid
gland showing that autoimmune thyroiditis was dramatically
exacerbated in anti-B7-1-treated NOD-B7-2KO-H-2h4 mice-
compared to untreated NOD-B7-2KO-H-2h4controls (Fig. 5B and C).
Thyroid lesions were also signiﬁcantly more severe in anti-B7-1-
treated NOD-B7-2KO-H-2h4 mice compared to anti-B7-1-treated
NOD-B7-2KO mice, in agreement with the strong contribution of
H-2h4 elements to the development of autoimmune thyroiditis on
the NOD background. As expected, NOD-B7-2KO mice demon-
strated severe inﬁltration in peripheral nerves but little evidence of
thyroiditis (Fig. 5B and C). Treatment with anti-B7-1 mAbs furtherA) 
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Fig. 5. Treatment with anti-B7-1 mAbs does not alter neuropathy and diabetes but exacerba
and NOD-B7-2KO controls were treated with anti-B7-1 mAbs between 2e4 weeks of age. A)
2KO mice. Similar results were observed in males and females and were pooled. B) Sciatic ner
for inﬁltration as indicated in Materials and methods. Statistical comparison of inﬁltration s
p < 0.0001). CeD) Representative sections of sciatic nerves (C) and thyroid glands (D) areexacerbated neuritis and restored insulitis (not shown) anddiabetes
in NOD-B7-2KO mice but failed to induce signiﬁcant inﬂammation
in the thyroid. Taken together, these results suggest that defective
immunoregulation can severely worsen underlying autoimmune
responses but does not alter the tissue tropism dictated by genetic
elements in the MHC region.
4. Discussion
In this study, we generated NOD-B7-2KO strains congenic at
various Idd loci in order to assess whether autoimmune diabetes
and neuropathy were controlled by common or distinct suscepti-
bility genes in the NOD background. We conclude that there is a
partial overlap in the genetic control of diabetes and neuropathy
that may reveal common defects and pathways leading to auto-
immunity. However, we also observed disease-speciﬁc features
that highlight complex interactions between susceptibility genes,
immunoregulation, and tissues targeted by autoimmunity. The
NOD H-2g7 MHC region appeared necessary for development of
both diabetes in NOD mice and neuropathy in NOD-B7-2KO mice.
In contrast, other Idd loci that strongly inﬂuence diabetes did not
affect neuropathy when considered individually, and even Idd
combinations that completely protect NODmice from disease had ates autoimmune thyroiditis in NOD-B7-2KO-H-2h4 congenic mice. NOD-B7-2KO-H-2h4
Cumulative incidence of neuropathy and diabetes in NOD-B7-2KO-H-2h4 and NOD-B7-
ves and thyroid glands were isolated from indicated mice, stained with H&E and scored
everity was performed using the ManneWhitney test (*: p < 0.05; **: p < 0.005, ****:
shown for indicated mice.
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resistance to disease provided by non-autoimmune gene segments
at distinct Idd loci was differentially overcome by defective
immunoregulation in a tissue/disease-speciﬁc manner. Thus, our
study helps identify Idd loci that control tissue-speciﬁc disease or
confer general susceptibility to autoimmunity, and brings insight to
the Treg-dependence of autoimmune processes inﬂuenced by given
Idd region.
Inﬁltration into sciatic nerves and development of peripheral
neuropathy were completely prevented in NOD-B7-2KO mice
when NOD H-2g7MH Calleles were replaced by H-2h4 or H-2b al-
leles. The dependence of autoimmune neuropathy on the H-2g7
MHC region was not surprising since it is also the most important
susceptibility region for autoimmune diabetes in mice and in
humans. In particular, Idd1, which encompasses the NOD H-2g7
region, is the only single locus that is necessary on its own for
development of autoimmune diabetes in NOD mice [18]. The
mechanisms by which MHC molecules control autoimmunity are
still not understood but recent advances in the molecular char-
acterization of peptide-MHC complexes targeted by autoreactive
CD4þ T cells in type 1 diabetes (T1D) and other autoimmune
diseases have shed some light on this issue [49]. In NOD mice,
crystal structure studies demonstrated that the binding-groove of
I-Ag7 molecules was permissive for binding of unique peptide
motifs in comparison to other MHC class II molecules that do not
predispose to autoimmunity [50,51]. This is signiﬁcant because
the ﬁne features of peptide binding and molecular pathway of
peptide presentation by MHC molecules are now believed to
affect the selection of autoreactive T cells in the thymus and their
activation in the periphery [52,53]. Thus, the dependence of
autoimmune neuropathy on the H-2g7 MHC in NOD-B7-2KO mice
could reﬂect altered presentation of self-peptides that compro-
mises thymic negative selection of T cells speciﬁc for peripheral
nerve antigens. In this regard, myelin P0is an important auto-
antigen in spontaneous and induced peripheral neuropathy [30],
and development of autoimmune neuropathy in NOD mice car-
rying a mutant allele of Aire was associated with reduced
expression of P0 in medullary thymic epithelial cells (mTECs) and
loss of tolerance to P0 [34]. The strong association of the H-2g7
MHC with both autoimmune diabetes and neuropathy indicate
that these genes may be associated with a general propensity to
autoimmunity. It is reminiscent of the association of given HLA
alleles with multiple autoimmune diseases in humans, such as the
association of the DR3-DQB1*0201 haplotype with T1D, Addison’s
disease, Graves’ disease, and Hashimoto’s thyroiditis [54]. How-
ever, one notable difference between T1D in NOD mice and
autoimmune neuropathy in NOD-B7-KO mice is that heterozygous
mice for the MHC region are completely protected from diabetes
but not neuropathy, although neuropathy is signiﬁcantly delayed
in heterozygous mice. This suggests that either non-autoimmune
MHC alleles are protective for T1D but not neuropathy, or H-2g7
MHC-linked susceptibility genes are dominant for both disease
but less penetrant for diabetes. Finally, it is worth noting that
NOD-H-2b mice deﬁcient for the immunoregulatory molecule PD-
1 were previously reported to develop autoimmune peripheral
neuropathy and other autoimmune diseases [32,55,56], demon-
strating that the H-2b MHC allows the selection of neuropathic T
cells. Thus, the fact that NOD-B7-2KO-H-2b/b mice do not develop
neuropathy indicates that neuropathy in NOD-B7-2KO mice does
not develop as a result of B7-2 deﬁciency being selectively
permissive for neuropathic T cells being selected by any given
MHC haplotype.
The occurrence of neuropathy in NOD-H-2b-PD-1KO but not PD-
1KOmice on a B6 or BALB/c background suggests that susceptibility
genes in non-MHC loci control the development of disease, at leastwhen it is mediated by H-2b-restricted neuropathic T cells. We
examined if autoimmune neuropathy is inﬂuenced by a number of
Idd loci that individually have a strong impact on T1D in NOD mice,
in that breeding resistance alleles at any of these single loci reduces
incidence of diabetes by 30 to 40 up to 100% with various effects on
insulitis. We found that neuropathy developed with normal ki-
netics and incidence in NOD-B7-2KO mice congenic for Idd3, Idd4,
Idd5, Idd9 or Idd10/18. Of note, we did not examine all Idd loci and it
is possible that susceptibility genes in Idd loci not tested here could
have a comparable inﬂuence on diabetes and neuropathy. Never-
theless, it is clear from our data that differences exist in the inﬂu-
ence on non-MHC genes on neuropathy versus diabetes in the NOD
background. Our results suggest that either the genetic control of
diabetes and neuropathy by non-MHC genes is completely distinct
or individual susceptibility genes at these loci have different levels
of penetrance for each disease. A distinct genetic control of diabetes
and neuropathy would be consistent with our previous report that
the effector mechanisms involved in each disease were different
[29], although susceptibility genes often inﬂuence the processes
leading to autoimmunity rather than mechanisms involved in tis-
sue destruction per se. Moreover, this is in partial agreement with a
study by Jiang et al who deﬁned non-MHC quantitative trait loci
(QTLs) that modify autoimmune phenotypes other than T1D
occurring in NOD-H-2b-PD-1KO mice, including peripheral neu-
ropathy [55]. They identiﬁed seven QTLs for peripheral neuropathy
and neuritis but only three out of seven overlappedwith known Idd
loci, namely Idd2, Idd9 and Idd15, indeed suggesting a different
genetic basis for neuropathy versus diabetes. In contrast with this
report, we did not observe an effect of Idd9 on neuropathy. This
discrepancy could be due to the size of genetic intervals since the
described QTL overlaps with Idd9 but may include additional genes.
Moreover, although the immunopathology of neuropathy in NOD-
B7-2KO versus NOD-H-2b-PD-1KO looked similar overall, it is
possible that disease is controlled by a different set of genes in each
strain, especially since the strains harbor different MHC alleles and
deﬁciencies in distinct costimulatory pathways, which all could
greatly impact the thymic selection of autoreactive T cells and their
activation in the periphery.
Despite the fact that individual Idd loci tested had no effect on
neuropathy in NOD-B7-2KO mice, we observed that both neuritis
and clinical disease were almost completely abrogated in NOD-B7-
2KO-Idd3/10/18, and NOD-B7-2KO-Idd3/5 mice developed severe
neuritis but not neuropathy. Thus, protective alleles for T1D on
chromosomes 1 and 3 also control autoimmune neuropathy but
require interactions between multiple loci to have an effect on
neuritis and clinical disease. This is reminiscent of the control of
insulitis in NOD mice. Indeed, while insulitis was linked only to
chromosomes 1 (Idd5) and 3 (Idd3 and Idd10/18) in the original
genome scan for susceptibility genes for diabetes [57,58], none of
these loci can independently protect from insulitis and interactions
between these loci are necessary to reduce insulitis [23,25,26]. In
NOD-B7-2KO mice, interactions between the Idd3 and Idd10/18
protective alleles appeared particularly potent since they could
almost completely abrogate both inﬂammation in peripheral
nerves and development of neuropathy. The fact that protective
alleles at both Idd3 and Idd5 did not reduce neuritis but prevented
disease as efﬁciently as Idd3/10/18 combination suggest that there
are discrete checkpoints in the development of autoimmune neu-
ropathy, similar to T1D [59e61], and that susceptibility genes in
distinct loci can differentially control individual checkpoints.
Moreover, our data indicate that a common locus can sometimes
interact with multiple other loci with a variable outcome on
different checkpoints. Finally, the similar protection for diabetes
and neuropathy provided by Idd3/5 and Idd3/10/18 loci indicates
there is a partial overlap in the genetic basis of these two
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of the results of several genome wide associations studies (GWAS)
that recently described a number of susceptibility genes associated
with a variety of autoimmune diseases, such IL-2, the IL-2 receptor
alpha chain (CD25), CTLA-4, and PTPN2, a phosphatase involved in
downstream signaling of the IL-2 receptor [62e66].
Candidate genes have been described for Idd loci on chromo-
somes 1 and 3. There is strong evidence that the Il2 gene is Idd3.
NOD susceptible alleles at Idd3 result in reduced IL-2 production
compared to B6 protective alleles [24], which has been shown to
negatively impact immunosuppression by Tregs and promote the
development of diabetes [67,68]. Peripheral neuropathy is
controlled by Tregs in NOD-B7-2KO mice since Treg depletion
following treatment with anti-B7-1 mAbs results in exacerbated
disease. In addition, effects of Idd3 may be compounded in NOD-
B7-2KO mice since interaction of B7-2 with CD28 has conse-
quences on both activation of autoreactive effector T cells (and
thus IL-2 production) and homeostasis of Tregs [46]. Idd3 is
nevertheless insufﬁcient by itself to control neuropathy, but in-
teracts with Idd5 and Idd10/18 regions to provide protection.
Among the two candidate genes at Idd5.1, i.e. Ctla4 and Icos,
accumulating data suggest that Ctla4 is responsible for the effect
of Idd5.1 on diabetes [39,69]. The NOD susceptibility allele at
Idd5.1 correlates with low levels of the ligand-independent form
of CTLA-4 (liCTLA-4), which can suppress T cell responses despite
its lack of a B7-binding domain [62,70,71]. Introduction of the
liCTLA-4 isoform in NOD mice reduced the incidence and severity
of disease [69,72]. Although we cannot exclude the role of other
genes, notably at Idd5.2 and Idd5.3, protection from disease but
not neuritis suggest that interactions between immune pathways
involving IL-2 and CTLA-4 are important to prevent inﬁltration in
peripheral nerves to evolve into tissue destruction and clinical
disease. Since CTLA-4 is important both to inhibit conventional T
cells and promote Treg function [73], it is possible that these in-
teractions occur within one cell subset or between different cell
subsets. Finally, a likely candidate for Idd10 is Cd101 [74]. CD101 is
expressed by multiple cell types, including Tregs, effector T cells
and dendritic cells. In particular, B6 protective alleles at Idd10
result in increased expression of CD101 in Tregs compared to NOD
alleles and CD101 expression levels on Tregs correlate with their
suppressive function [74,75]. While additional studies would be
needed to conﬁrm that protection from neuritis and neuropathy
in NOD-B7-2KO-Idd3/10/18 mice results from interactions be-
tween Idd3/Il2 and Idd10/Cd101, it is tempting to speculate
that these interactions could improve both the number and
function of Tregs and that protection by Idd3/10/18 is thus largely
Treg-mediated.
To directly compare the impact of protective Idd3/5 and Idd3/
10/18 alleles on neuropathy versus diabetes, we took advantage of
the development of diabetes and neuropathy in NOD-B7-2KO mice
treatedwith anti-B7-1 mAbs between 2 and 4 wk of age [29,46].
We previously showed that the accelerated and concomitant
development of both diseases in anti-B7-1-treated NOD-B7-2KO
mice was likely due to defective immunoregulation stemming
from reduced numbers of Tregs, although a role for abrogated
CTLA-4 signaling has not been excluded. Here, we found that
treatment of NOD-B7-2KO-Idd3/5 and NOD-B7-2KO-Idd3/10/18
congenic mice with anti-B7-1 mAbs restored neuropathy but not
diabetes. This indicates that the protection afforded by Idd3/5 and
Idd3/10/18 is stronger for diabetes than neuropathy, suggesting
that susceptibility genes at these loci play a more integral role in
autoimmune responses targeting pancreatic islets compared to
peripheral nerves. Of note, the fact that NOD-B7-2KO-Idd3/5 and
NOD-B7-2KO-Idd3/10/18 are still protected from diabetes after
treatment with anti-B7-1mAbs, i.e. in a model where diabetesoccurs as a consequence of a defective Treg compartment, sug-
gests that Idd3/5 and Idd3/10/18 alleles are protective for diabetes
in a Treg-independent manner. In contrast, Treg deﬁciency abro-
gated the protective effect of Idd3/5 and Idd3/10/18 on neuropathy,
which is consistent with interaction of candidate genes at these
loci having a protective effect on neuropathy due to a major
impact on Tregs. Surprisingly, the protective effect of Idd3/5 on
sialadenitis was also abrogated after anti-B7-1 treatment. This was
unexpected since NOD susceptibility alleles at Idd3 and Idd5 were
previously shown to be necessary and sufﬁcient for the develop-
ment of sialadenitis [76,77]. This result suggests that given genes
and pathways that control autoimmunity in the NOD mouse may
be overridden in conditions of defective immunoregulation in a
tissue/disease-speciﬁc manner. Conversely, the effects of MHC al-
leles on disease were unaffected by Treg depletion, as evidenced
by the clear tissue polarization in NOD-B7-2KO versus NOD-B7-
2KO-H-2h4 mice that remains unaffected after anti-B7-1 treat-
ment. Namely, anti-B7-1-treated NOD-B7-2KO mice develop
neuropathy and diabetes but not thyroiditis, whereas anti-B7-1-
treated NOD-B7-2KO-H-2h4 mice develop severe thyroiditis but
not diabetes or neuropathy. Of note, thyroiditis did not appear to
develop in untreated NOD-B7-2KO-H-2h4 mice, even after 60 wks
of age. This differs from the NOD-H-2h4 strain, in which two-third
of animals spontaneously develop thyroid lesions after 6 months
of age without iodine supplementation in the drinking water [48],
and likely reﬂects the fact that B7-2 deﬁciency prevents a number
of autoimmune syndromes that normally develop in NOD mice,
such as diabetes and sialadenitis [4,78]. The dramatic increase in
the severity of thyroiditis in anti-B7-1-treated NOD-B7-2KO-H-2h4
mice compared to untreated mice is consistent with the previously
reported role of Tregs in controlling thyroiditis in NOD-H-2h4 mice
[79,80].
In conclusion, we showed that autoimmune neuropathy and
diabetes on the NOD background have an overlapping but distinct
genetic basis. Additionally, we found potent genetic interactions of
some Idd loci that provided almost complete protection from
neuritis and clinical neuropathy, and further showed that defec-
tive immunoregulation by Tregs could supersede protection by
some, but not other, Idd loci in a tissue-speciﬁc manner. Taken
together, these ﬁndings have implications for the identiﬁcation of
susceptibility genes for autoimmune peripheral neuropathy.
Moreover, our study uncovers that the inﬂuence of protective
alleles on autoimmune diseases can be differentially affected by
Treg defects depending on the tissue target by autoimmunity,
indicating the complexity of deﬁning the genetic basis of auto-
immune diseases.
Finally, this paper is part of a dedicated issue of the Journal of
Autoimmunity devoted in this case to Professor Abul Abbas, part of the
Journal’smissionwithin the last several years to highlight distinguished
immunologists. In my case, I have known Abul formany years, but have
only begun to appreciate his rock star talents during the past dozen
years at the University of California at San Francisco. Abul, you have an
amazing ability to make things simple for the beginning immunologist
while performing in depth research that transforms our understanding
of immunology. Your multiple books and lectures around the world
have inﬂuenced so many and created passion among immunology re-
searchers very few people in all of science can match. The rock star
designation is apropos and the only thing I am missing is your auto-
graph on a golf ball.
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